EGFR and colorectal neoplasm: Given that EGFR, a transmembrane receptor tyrosine kinase, is overexpressed in 25%–75% of colorectal tumors [38,39], a significant proportion of patients that may benefit from anti-EGFR agents may also have KRAS mutation.